From Fitness Tracker to Clinical Trial Tool
Galaxy Watch clinical trials refer to drug studies that use biometric data from Samsung’s consumer smartwatches, collected during participants’ everyday life, as regulated digital health endpoints to evaluate safety, efficacy, and patient outcomes within formal clinical research workflows. This shift turns wearable biometric data pharma teams once saw as consumer-grade signals into potential clinical evidence. Samsung Electronics announced on June 24 that it will use biometric data from Galaxy Watch devices in clinical trials for new drug development, through a partnership with digital clinical research company Alcedis. This is not a minor feature update; it is an attempt to plug a mass‑market wearable directly into the machinery of drug research. If successful, it will prove that clinical research wearables drawn from the consumer market can stand up to the demands of regulated trials.
Why Pharma Cares About Digital Health Endpoints Now
The deeper story is that drug makers are desperate for better digital health endpoints, and wearables are the most obvious source. Clinical trials still depend heavily on clinic visits, sporadic measurements, and self‑reported symptoms, which miss what happens between appointments. Galaxy Watch sensors can fill that gap by collecting continuous health metrics in real‑world environments and converting them into clinical endpoints for investigational drugs. Samsung has been building toward this moment by expanding a connected‑care ecosystem that links wearable health data with healthcare services and acquiring Xealth, a platform that connects hospitals to digital solutions. In plain terms, Samsung is turning its watch from a wellness accessory into infrastructure, betting that wearable biometric data pharma teams can trust will become a prized currency in research.
How the Samsung–Alcedis Partnership Rewires Trial Operations
The partnership with Alcedis is designed to do the hard operational work of clinical research wearables, not just proof‑of‑concept demos. Under the agreement, Samsung and Alcedis will jointly develop methods to convert Galaxy Watch biometrics into validated endpoints and biomarkers for drug safety, efficacy, and patient outcomes. Samsung provides the devices, biosensors and research platform that collect physiological data from consented users in everyday settings, including advanced signals such as bioelectrical impedance analysis and electrodermal activity, plus Software as a Medical Device features that can detect obstructive sleep apnea and atrial fibrillation. Alcedis leads study execution, participant engagement, data collection, monitoring, and regulatory compliance. According to Samsung’s Jongmin Choi, “The future of clinical research is increasingly collaborative and brings together technology, scientific expertise, and research partners to generate a deeper understanding of human health”.
What Changes for Patients and Healthcare IT
For participants, the promise is simple: fewer burdens, more meaningful data. Wearables offer a model where health signals are captured during everyday life rather than only in clinics. If Galaxy Watch clinical trials work as intended, operators could monitor people more continuously, rely less on scheduled visits, and collect data that better reflects daily conditions. That could accelerate timelines and improve compliance because at‑home monitoring fits more naturally into routine than repeated trips to research sites. Samsung explicitly frames this as ensuring that data generated in everyday life contributes to drug‑development research and innovations that benefit patients. But healthcare IT teams face the hard questions: can this data be secured, validated, audited, and integrated into existing regulated workflows? Consent, identity, device management, data security, audit trails and interoperability all become more complex when consumer wearables enter formal clinical infrastructures.
Consumer Wearables Are Crossing the Regulatory Line
The most important consequence of Samsung’s move is symbolic: consumer wearables are crossing the line into regulated clinical research infrastructure. Wearable health data is moving beyond step counts and sleep scores, and the Galaxy Watch is now positioned as a source of clinical research wearables evidence rather than lifestyle insights. Samsung plans to integrate Galaxy‑generated health data with hospital electronic health record systems, which would knit its devices into the heart of care and research rather than leave them at the consumer edge. Hanno Härtlein of Alcedis argues that “The future of clinical research depends on our ability to capture meaningful health data beyond traditional clinical settings”. The real test will be whether Galaxy Watch biometrics can move from useful signals to data regulators and sponsors consider dependable. If they pass, smartwatches stop being gadgets and start being instruments—and drug development will have to adapt.
